Phase I-II study of ADXS31-142 alone and in combination with pembrolizumab in patients with previously treated metastatic castration-resistant prostate cancer (mCRPC): the KEYNOTE-046 trial

Naomi B Haas1*, Mark N Stein2, Ronald Tutrone3, Rodolfo Perini4, Andrew Denker4, David Mauro5, Lawrence Fong6

From 30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015)
National Harbor, MD, USA. 4-8 November 2015

Background
Activation of tumor antigen-specific T-cell responses and bypass/neutralization of tumor immune tolerance mechanisms are essential for immunotherapeutic efficacy. *Listeria monocytogenes* (*Lm*)-listeriolysin O (LLO) immunotherapies have shown to both generate antigen-specific T-cell responses and neutralize cells that protect the tumor microenvironment. ADXS31-142 is a live attenuated *Lm*-LLO immunotherapy designed to target the prostate-specific antigen (PSA) and bioengineered to secrete an antigen-adjuvant fusion protein, consisting of a truncated fragment of the LLO fused to human PSA. Programmed death receptor 1 (PD-1) is a cell surface protein receptor central to T-cell immunity inhibition. Pembrolizumab is a humanized monoclonal antibody that binds to the PD-1 receptor, blocking interaction with PD-1 ligands and thereby inhibiting tumor immune evasion mechanisms. The combination of an *Lm*-LLO immunotherapy with an anti-PD-1 antibody has shown synergistic antitumor activity in preclinical studies.

Methods
This is a Phase I-II, open-label, multicenter, nonrandomized, 2-part study (NCT02325557) in patients with mCRPC. Part A is a dose escalation of monotherapy ADXS31-142, followed by Part B, a dose escalation of ADXS31-142 plus pembrolizumab; Part B is followed by a dose-expansion cohort. Primary objectives are to evaluate the safety and tolerability of ADXS31-142 alone and in combination with pembrolizumab, and establish the ADXS31-142 recommended Phase II dose (RP2D) for monotherapy and combination therapy. Secondary objectives include evaluation of antitumor activity and progression-free survival. Male patients (≥18 years) with progressive mCRPC (≤3 prior systemic treatment regimens), on androgen deprivation therapy, and with an Eastern Cooperative Oncology Group (ECOG) performance status of 0–1 are eligible. Each dose-determining part will enroll up to 21 patients. ADXS31-142 and pembrolizumab (200 mg) are administered once every 3 weeks in a 12-week treatment cycle, with ADXS31-142 administration limited to weeks 1, 4, and 7. ADXS31-142 dose-escalations (up to a maximum of 1×10¹⁰ colony-forming units [CFU]) and de-escalations are done according to predefined dose-limiting toxicity criteria by applying the modified toxicity probability interval design. In Part A, the starting ADXS31-142 dose is 1×10⁹ CFU, and in Part B is either 1 level below the RP2D established for monotherapy or 1×10⁹ CFU, if this was the maximum tolerated dose for monotherapy. Once the ADXS31-142 RP2D for combination with pembrolizumab is determined, the expansion cohort will open for enrollment. A total of 30 patients are planned for treatment at the RP2D. The study is currently open and patient accrual is in progress.

Trial registration
ClinicalTrials.gov identifier NCT02325557.
http://www.immunotherapyofcancer.org/content/3/S2/P153

Published: 4 November 2015

doi:10.1186/2051-1426-3-S2-P153
Cite this article as: Haas et al.: Phase I-II study of ADXS31-142 alone and in combination with pembrolizumab in patients with previously treated metastatic castration-resistant prostate cancer (mCRPC); the KEYNOTE-046 trial. Journal for ImmunoTherapy of Cancer 2015 3(Suppl 2):P153.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit